Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Fate Therapeutics Inc shares valued at $9,573 were sold by TAHL CINDY on Aug 04 ’25. At $1.06 per share, TAHL CINDY sold 9,037 shares. The insider’s holdings dropped to 397,670 shares worth approximately $0.4 million following the completion of this transaction.
Also, Valamehr Bahram sold 14,466 shares, netting a total of over 15,396 in proceeds. Following the sale of shares at $1.06 each, the insider now holds 334,898 shares.
Before that, TAHL CINDY had added 9,037 shares to its account. In a trade valued at $9,573, the Officer bought Fate Therapeutics Inc shares for $1.06 each.
As published in a research note from BofA Securities on November 18, 2024, Fate Therapeutics Inc [FATE] has been rated up from an Underperform to a Neutral. Analysts at Piper Sandler upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in mid June. Earlier on January 24, 2023, H.C. Wainwright downgraded its rating. Their new recommendation was “a Neutral” for FATE stock which previously was a “a Buy”.
Analyzing FATE Stock Performance
On last trading session, Fate Therapeutics Inc [NASDAQ: FATE] rose 5.26% to $1.0. The stock’s lowest price that day was $0.9649, but it reached a high of $1.02 in the same session. During the last five days, there has been a drop of approximately -1.96%. Over the course of the year, Fate Therapeutics Inc shares have dropped approximately -74.75%.
Is Fate Therapeutics Inc subject to short interest?
Stocks of Fate Therapeutics Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.37 million shares to 9.65 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 9.28 million shares. A jump of 3.87% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.71 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.71.
Which companies own the most shares of Fate Therapeutics Inc (FATE)?
In terms of Fate Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7.5 in the next 12 months, up nearly 689.47% from the previous closing price of $0.95. Analysts anticipate Fate Therapeutics Inc stock to reach 145 by 2025, with the lowest price target being 3. In spite of this, 8 analysts ranked Fate Therapeutics Inc stock as Buy at the end of 2025. On January 06, 2023, Wedbush assigned a price target of “a Neutral” to the stock and downgraded coverage with a $7.
